SeedFolio
Deals on record
1
Common Fundraising Type
Seed
HDAX Therapeutics
Preclinical development
HDAX Therapeutics is developing next-generation HDAC6 inhibitors to treat neurological and cardiometabolic diseases.
Deals on record
Common Fundraising Type
Preclinical development
HDAX Therapeutics is developing next-generation HDAC6 inhibitors to treat neurological and cardiometabolic diseases.